256 related articles for article (PubMed ID: 16740766)
1. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
[TBL] [Abstract][Full Text] [Related]
4. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
[TBL] [Abstract][Full Text] [Related]
5. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
6. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases.
Elkord E; Dangoor A; Drury NL; Harrop R; Burt DJ; Drijfhout JW; Hamer C; Andrews D; Naylor S; Sherlock D; Hawkins RE; Stern PL
J Immunother; 2008; 31(9):820-9. PubMed ID: 18833005
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
Amato RJ; Hawkins RE; Kaufman HL; Thompson JA; Tomczak P; Szczylik C; McDonald M; Eastty S; Shingler WH; de Belin J; Goonewardena M; Naylor S; Harrop R
Clin Cancer Res; 2010 Nov; 16(22):5539-47. PubMed ID: 20881001
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Griffiths R; Steven N; Hawkins RE
Cancer Immunol Immunother; 2008 Jul; 57(7):977-86. PubMed ID: 18060404
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.
Hawkins RE; Macdermott C; Shablak A; Hamer C; Thistlethwaite F; Drury NL; Chikoti P; Shingler W; Naylor S; Harrop R
J Immunother; 2009 May; 32(4):424-9. PubMed ID: 19342962
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
[TBL] [Abstract][Full Text] [Related]
13. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
Harrop R; Chu F; Gabrail N; Srinivas S; Blount D; Ferrari A
Cancer Immunol Immunother; 2013 Sep; 62(9):1511-20. PubMed ID: 23877659
[TBL] [Abstract][Full Text] [Related]
16. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
[TBL] [Abstract][Full Text] [Related]
17. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
18. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
19. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
Elkord E; Dangoor A; Burt DJ; Southgate TD; Daayana S; Harrop R; Drijfhout JW; Sherlock D; Hawkins RE; Stern PL
Cancer Immunol Immunother; 2009 Oct; 58(10):1657-67. PubMed ID: 19221742
[TBL] [Abstract][Full Text] [Related]
20. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
